雷洛昔芬用于骨质疏松症的兴衰,1999-2022年
该研究基于加拿大安大略省社区居住的≥66岁女性,描述了1999年5月至2022年12月间启动雷洛昔芬治疗的趋势。雷洛昔芬起始使用在2001年达到高峰后下降,2012年后总体使用量快速下降,但每年仍有约1000人持续用药,作者认为其在特定骨质疏松患者中仍是相关选择。
要点
- 雷洛昔芬年起始人数在2001年达高峰3824人,2002年下降15%至3252人,2003年2113人降至2022年90人。
- 每年仍在用药的现患用户数在2003至2011年间保持>5000人,从2012年4670人降至2022年959人。
- 总体29%的患者持续治疗≥3年,作者认为雷洛昔芬在特定骨质疏松患者中仍是相关选择。
核心结论
- 雷洛昔芬起始使用自2003年以来大幅下降,总体使用量自2012年以来快速下降。
- 近年每年新起始者不足100人,但每年仍有约1000人继续服用雷洛昔芬,作者认为其在特定骨质疏松患者中仍是相关选择。
研究设计与样本
- 通过安大略药物福利计划识别1999年5月至2022年12月间启动雷洛昔芬的社区居住≥66岁女性,按日历年绘制新起始和现患用户数,并使用60天允许间隔估算持续治疗。
- 共纳入21896名合格女性,平均年龄74.2岁(SD=6.2),5%有骨折史,57%有口服双膦酸盐使用史。
主要发现
- 启动雷洛昔芬的年人数增至2001年高峰3824人,2002年下降15%至3252人,随后从2003年2113人逐渐降至2022年90人。
- 现患用户数在2003至2011年间每年保持>5000人,从2012年4670人逐渐降至2022年959人。
- 总体29%的患者持续治疗≥3年。
- 除已知的人群层面治疗趋势(他汀类增加、雌激素治疗减少)外,患者特征随时间变化差异很小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The relevance of raloxifene in current osteoporosis practice is not clear given concerns about its safety and the introduction of newer therapeutic options. We describe the rise and fall in raloxifene use among older females in Ontario, documenting that it remains an important therapeutic option for osteoporosis in select patients. PURPOSE: Raloxifene has been available in Canada for postmenopausal osteoporosis since 1998. However, its benefit-to-risk ratio became questioned after evidence of increased risk of thrombosis and fatal stroke emerged in the early 2000s. We aimed to describe the use of raloxifene over time. METHODS: We identified community-dwelling females aged ≥ 66 years initiating raloxifene between 1999/05 and 2022/12 through the Ontario Drug Benefit program, plotted the number of incident and prevalent users by calendar year, and estimated persistence with therapy using a 60-day permissible gap. Patient characteristics were described using medical and pharmacy claims within the year prior to initiation. RESULTS: We identified 21,896 eligible females (mean age = 74.2 [SD = 6.2] years, 5% fracture history, 57% oral bisphosphonate history). The number of patients initiating raloxifene increased to an annual high of 3,824 in 2001 followed by a 15% drop in 2002 (n = 3,252) before a gradual decline from 2,113 in 2003 to 90 in 2022. In contrast, the number of prevalent users remained >5,000 annually between 2003 and 2011, with a gradual drop from 4,670 in 2012 to 959 in 2022. Overall, 29% persisted with therapy for ≥ 3 years. Besides known population-level treatment trends (increased statins, decreased estrogen therapy), little differences in patient characteristics were identified over time. CONCLUSION: Raloxifene initiation has declined substantially since 2003, and overall utilization has declined rapidly since 2012. While less than 100 initiators were identified annually in recent years, around 1,000 continue to take raloxifene every year. Raloxifene thus remains a relevant option among select patients with osteoporosis.
引用
- Shogry FF, Hayes KN, Kim S, et al. The rise and fall of raloxifene use for osteoporosis, 1999-2022. Osteoporos Int. 2025. PMID: 40498127. doi:10.1007/s00198-025-07544-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。